Aldolase promotes the development of cardiac hypertrophy by targeting AMPK signaling

[1]  M. Zhou,et al.  Upregulation of the ALDOA/DNA-PK/p53 pathway by dietary restriction suppresses tumor growth , 2018, Oncogene.

[2]  B. Viollet,et al.  AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation , 2018, Nature Communications.

[3]  De-Pei Liu,et al.  SIRT2 Acts as a Cardioprotective Deacetylase in Pathological Cardiac Hypertrophy , 2017, Circulation.

[4]  S. V. Heesch,et al.  IL-11 is a crucial determinant of cardiovascular fibrosis , 2017, Nature.

[5]  M. Huang,et al.  Feedback regulation of ALDOA activates the HIF-1α/MMP9 axis to promote lung cancer progression. , 2017, Cancer letters.

[6]  Sheng-Cai Lin,et al.  Fructose-1,6-bisphosphate and aldolase mediate glucose sensing by AMPK , 2017, Nature.

[7]  D. Hardie,et al.  AMP-Activated Protein Kinase: An Ubiquitous Signaling Pathway With Key Roles in the Cardiovascular System , 2017, Circulation research.

[8]  A. Nelson,et al.  Aldolase-catalysed stereoselective synthesis of fluorinated small molecules. , 2017, Current opinion in chemical biology.

[9]  L. Guarente,et al.  Metabolic control of primed human pluripotent stem cell fate and function by the miR-200c–SIRT2 axis , 2017, Nature Cell Biology.

[10]  G. He,et al.  Abstract 19668: Caspase Recruitment Domain-Containing Protein 9 Knockout Rescues Heart Function by Reducing Fibrosis and Hypertrophy in a Pressure-Overload Model of Murine Heart Failure , 2016 .

[11]  Thomas J. Wang,et al.  Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association. , 2016, Circulation research.

[12]  Yi Qin,et al.  ALDOA functions as an oncogene in the highly metastatic pancreatic cancer. , 2016, Cancer letters.

[13]  K. Sharma,et al.  Therapeutic Potential of AICAR in Attenuating Obesity‐Induced Metabolic, Liver and Kidney Disease , 2016 .

[14]  N. Rosenthal,et al.  Revisiting Cardiac Cellular Composition. , 2016, Circulation research.

[15]  S. Sengupta,et al.  Comparative Proteome Profiling during Cardiac Hypertrophy and Myocardial Infarction Reveals Altered Glucose Oxidation by Differential Activation of Pyruvate Dehydrogenase E1 Component Subunit β. , 2015, Journal of molecular biology.

[16]  R. Ventura-clapier,et al.  Is Inhibition of Hypertrophy a Good Therapeutic Strategy in Ventricular Pressure Overload?: Inhibition of Hypertrophy, Per Se, May Not Be a Good Therapeutic Strategy in Ventricular Pressure Overload Other Approaches Could Be More Beneficial , 2015, Circulation.

[17]  Joseph A. Hill,et al.  Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. , 2015, Circulation.

[18]  Michael Simons,et al.  Endothelial cell metabolism in normal and diseased vasculature. , 2015, Circulation research.

[19]  K. Otsu,et al.  MicroRNA-451 Exacerbates Lipotoxicity in Cardiac Myocytes and High-Fat Diet-Induced Cardiac Hypertrophy in Mice Through Suppression of the LKB1/AMPK Pathway , 2015, Circulation research.

[20]  J. Dyck,et al.  Resveratrol Treatment of Mice With Pressure-Overload–Induced Heart Failure Improves Diastolic Function and Cardiac Energy Metabolism , 2015, Circulation. Heart failure.

[21]  BertrandCrozatier,et al.  Inhibition of Hypertrophy, Per Se, May Not Be a Good Therapeutic Strategy in Ventricular Pressure Overload: Other Approaches Could Be More Beneficial , 2015 .

[22]  D. Hardie.  AMPK--sensing energy while talking to other signaling pathways. , 2014, Cell metabolism.

[23]  B. Viollet,et al.  Metformin: from mechanisms of action to therapies. , 2014, Cell metabolism.

[24]  J. Casanova,et al.  A Thermolabile Aldolase A Mutant Causes Fever-Induced Recurrent Rhabdomyolysis without Hemolytic Anemia , 2014, PLoS genetics.

[25]  K. Fujiu,et al.  Fibroblast-mediated pathways in cardiac hypertrophy. , 2014, Journal of molecular and cellular cardiology.

[26]  P. Doevendans,et al.  Inhibition of miR-25 Improves Cardiac Contractility in the Failing Heart , 2014, Nature.

[27]  Torsten Doenst,et al.  Cardiac Metabolism in Heart Failure: Implications Beyond ATP Production , 2013, Circulation research.

[28]  F. Villarroya,et al.  Fibroblast growth factor 21 protects against cardiac hypertrophy in mice , 2013, Nature Communications.

[29]  G. Lopaschuk,et al.  Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload. , 2013, Cardiovascular research.

[30]  L. Young,et al.  AMP-Activated Protein Kinase Regulation and Biological Actions in the Heart , 2012, Circulation research.

[31]  Xinli Hu,et al.  Left Ventricular Failure Produces Profound Lung Remodeling and Pulmonary Hypertension in Mice: Heart Failure Causes Severe Lung Disease , 2012, Hypertension.

[32]  D. Mancini,et al.  Adipose Tissue Inflammation and Adiponectin Resistance in Patients With Advanced Heart Failure: Correction After Ventricular Assist Device Implantation , 2012, Circulation. Heart failure.

[33]  N. Sundaresan,et al.  Exogenous NAD Blocks Cardiac Hypertrophic Response via Activation of the SIRT3-LKB1-AMP-activated Kinase Pathway* , 2009, The Journal of Biological Chemistry.

[34]  L. Sibley,et al.  Aldolase is essential for energy production and bridging adhesin-actin cytoskeletal interactions during parasite invasion of host cells. , 2009, Cell host & microbe.

[35]  B. Viollet,et al.  AMPKalpha2 counteracts the development of cardiac hypertrophy induced by isoproterenol. , 2008, Biochemical and biophysical research communications.

[36]  David A. Kass,et al.  Tackling heart failure in the twenty-first century , 2008, Nature.

[37]  E. Olson,et al.  Cardiac plasticity. , 2008, The New England journal of medicine.

[38]  Stefan Neubauer,et al.  The failing heart--an engine out of fuel. , 2007, The New England journal of medicine.

[39]  M. Skinner,et al.  Human Amyloidogenic Light Chains Directly Impair Cardiomyocyte Function Through an Increase in Cellular Oxidant Stress , 2004, Circulation research.

[40]  L. Goodyear,et al.  Increased Adenosine Monophosphate–Activated Protein Kinase Activity in Rat Hearts With Pressure-Overload Hypertrophy , 2001, Circulation.